

22 December 2016

## United Greeneries Commences Cannabis Cultivation

- **Cannabis cultivation underway at world-class Duncan Facility following securing of all required starter materials**
- **First cannabis harvest expected within 90 days of cultivation start-up**
- **MMJ to provide Canadian consumers with access to one of the largest cannabis catalogues available via simultaneous cultivation of multiple strains**
- **Duncan Facility expansion strategy targeting ultimate production of circa 60,000kg of cannabis to supply the soon to be legalised Canadian recreational market**

**MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”)** is pleased to advise that its Canadian-based subsidiary, United Greeneries Ltd (“UG”) has commenced cannabis growing operations at its state-of-the-art Duncan Facility.

The commencement of cultivation follows the recent securing of an Import Permit from Health Canada (“HC”) and the Canadian Food Inspection Agency (“CFIA”), allowing for the importation of 1kg of cannabis seeds.

As previously advised, UG will undertake the staged expansion of the Duncan Facility, with initial earmarked production of circa 7,500kg of cannabis by the end of 2018, following the facility’s first full year of production. UG plans to then rapidly scale up the production capacity of the Duncan Facility to circa 60,000kg.

### **MMJ PhytoTech’s Managing Director, Andreas Gedeon, commented:**

“We are very pleased to have commenced growing operations at our Duncan Facility, as it represents a significant milestone towards becoming a low-cost, large-scale cannabis producer in the Canadian market.

We expect to receive the first harvest from Duncan in Q1 2017, with the aim of scaling up production next year in order to penetrate both the existing medicinal and soon to be legalised recreational markets, which will have a combined estimated value of C\$8-9 billion per annum by 2024.

We look forward to providing our shareholders with further corporate and operational updates in the near-term.”

-ENDS-

**For media and investor inquiries please contact:**

**Andreas Gedeon**  
**Managing Director**  
**+1 (250) 713 6302**  
**agedeon@mmj.ca**

**Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067**



**Follow us on Twitter @MMJPhytoTechLtd**

<http://www.mmjphytotech.com.au>

**About MMJ PhytoTech Limited**

**MMJ PhytoTech Limited (ASX. MMJ)** is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

The Company is currently in the process of finalising a transaction with Canadian-based Harvest One Capital Corp. (“Harvest One”) (TSXV NEX: WON.H) for the listing of the MMJ’s core cannabis subsidiaries on the TSX-V via the reverse takeover of Harvest One.

**United Greeneries Holding Ltd.** has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

The Company’s European, cannabis-based, pharmaceutical, nutraceutical and cosmetics division operates under its 100% owned subsidiary, **Satipharm AG**. MMJ began production of its Gelpell® Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.

MMJ’s Israel-based subsidiary, **PhytoTech Therapeutics Ltd**, is responsible for the Company’s R&D activities, with a key focus on the development and commercialisation of new and existing delivery systems and devices that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients.